Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in a patient with refractory Behçet's disease uveitis and concomitant bladder papillary carcinoma

Donato Rigante

doi:10.1111/imj.13538

Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in a patient with refractory Behçet's disease uveitis and concomitant bladder papillary carcinoma

Donato Rigante

Research output: Contribution to journal › Article

6 Citations (Scopus)

Abstract

The authors describe a patient with Behçet's disease treated with anakinra and canakinumab after bladder papillary cancer excision. The same patient had been previously proven to be unresponsive to standard therapy, including TNF-α inhibitors.

Original language	English
Pages (from-to)	1-5
Number of pages	5
Journal	Internal Medicine Journal
Volume	2017
DOIs	https://doi.org/10.1111/imj.13538
Publication status	Published - 2017

Keywords

Behçet's disease

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/imj.13538

Cite this

@article{9406a8712a3447c2a330161c8b179ed6,

title = "Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in a patient with refractory Beh{\c c}et's disease uveitis and concomitant bladder papillary carcinoma",

abstract = "The authors describe a patient with Beh{\c c}et's disease treated with anakinra and canakinumab after bladder papillary cancer excision. The same patient had been previously proven to be unresponsive to standard therapy, including TNF-α inhibitors.",

keywords = "Beh{\c c}et's disease, Beh{\c c}et's disease",

author = "Donato Rigante",

year = "2017",

doi = "10.1111/imj.13538",

language = "English",

volume = "2017",

pages = "1--5",

journal = "Internal Medicine Journal",

issn = "1445-5994",

publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in a patient with refractory Behçet's disease uveitis and concomitant bladder papillary carcinoma

AU - Rigante, Donato

PY - 2017

Y1 - 2017

N2 - The authors describe a patient with Behçet's disease treated with anakinra and canakinumab after bladder papillary cancer excision. The same patient had been previously proven to be unresponsive to standard therapy, including TNF-α inhibitors.

AB - The authors describe a patient with Behçet's disease treated with anakinra and canakinumab after bladder papillary cancer excision. The same patient had been previously proven to be unresponsive to standard therapy, including TNF-α inhibitors.

KW - Behçet's disease

UR - http://hdl.handle.net/10807/105214

U2 - 10.1111/imj.13538

DO - 10.1111/imj.13538

M3 - Article

SN - 1445-5994

VL - 2017

SP - 1

EP - 5

JO - Internal Medicine Journal

JF - Internal Medicine Journal

ER -

Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in a patient with refractory Behçet's disease uveitis and concomitant bladder papillary carcinoma

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this